Ep 10: Insitro CEO Daphne Koller on Using ML to Change Drug Discovery
Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech.
Unsupervised Learning with Jacob Effron · Jacob Effron, Daphne Koller
Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech.
(00:00) - intro
(00:54) - Daphne’s journey
(09:18) - AI and biology discovery
(10:59) - insitro vs. traditional pharma
(20:04) - phenotyping patients
(26:01) - early mistakes
(29:51) - the future of data
(35:33) - partnering with larger pharma companies
(38:17) - impact of LLMs on biopharma
(44:04) - over-hyped/under-hyped
With your co-hosts:
@jasoncwarner - Former CTO GitHub, VP Eng Heroku & Canonical
@ericabrescia - Former COO Github, Founder Bitnami (acq’d by VMWare)
@patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn
@jacobeffron - Partner at Redpoint, Former PM Flatiron Health